What amount sold does Lifeward Ltd. report in Form D filings?

The latest linked filings report $110M sold across 10 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was Lifeward Ltd.'s most recent SEC filing?

Lifeward Ltd.'s most recent Form D filing was on 2026-07-08.

How many investors does Lifeward Ltd. have?

The most recent Form D filing lists 5 investor(s).

What type of securities does Lifeward Ltd. offer?

Lifeward Ltd.'s SEC Form D filings indicate equity, debt offerings.

Lifeward Ltd.

CIK: 0001607962·Biotechnology·HUDSON, MA·Other

Reported Sold

$109,953,772

Total Filings

Identified Offerings

Last Filed

Jul 8, 2026

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Biotechnology industry

SEC EDGAR

Offering filing timeline

Jul 8, 2026Form D — New notice

Reported sold: $11,160,000 · Target: Indefinite

Rule 506(b)·5 investors

Apr 2, 2026Form D — New notice

Reported sold: $20,000,000 · Target: Indefinite

Rule 506(b)·2 investors

Jan 13, 2025Form D — New notice

Reported sold: $5,000,003 · Target: $5,000,003

Rule 506(b)·4 investors

Oct 6, 2021Form D — New notice

Reported sold: $16,293,754 · Target: $16,293,754

Rule 506(b)·9 investors

Feb 26, 2021Form D — New notice

Reported sold: $40,000,001 · Target: $40,000,001

Rule 506(b)·22 investors

Dec 18, 2020Form D — New notice

Reported sold: $8,000,004 · Target: $8,000,004

Rule 506(b)·7 investors

Jul 8, 2020Form D — New notice

Reported sold: $4,500,006 · Target: $8,845,690

Rule 506(b)·11 investors

Jun 19, 2019Form D — New notice

Reported sold: $0 · Target: $10,849,987

Rule 506(b)·5 investors

Jun 19, 2019Form D — New notice

Reported sold: $0 · Target: $135,000

Rule 506(c)·5 investors

Jun 19, 2019Form D — New notice

Reported sold: $5,000,004 · Target: $7,500,006

Rule 506(b)·2 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

$9,323,663

Amendment Rate

Latest reported sold across 10 identified offerings

$109,953,772

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

John William Poduska

Related Person

Appears on 8 filings

Larry Jasinski

Related Person

Appears on 8 filings

Yohanan Engelhardt

Related Person

Appears on 7 filings

Jeff Dykan

Related Person

Appears on 7 filings

Wayne B. Weisman

Related Person

Appears on 7 filings

Ori Gon

Related Person

Appears on 7 filings

Ofir Koren

Related Person

Appears on 5 filings

Yasushi Ichiki

Related Person

Appears on 4 filings

Filing History

Date	Type	Offering target	Reported sold	Investors
Jul 8, 2026	New	Indefinite	$11,160,000	5
Apr 2, 2026	New	Indefinite	$20,000,000	2
Jan 13, 2025	New	$5,000,003	$5,000,003	4
Oct 6, 2021	New	$16,293,754	$16,293,754	9
Feb 26, 2021	New	$40,000,001	$40,000,001	22
Dec 18, 2020	New	$8,000,004	$8,000,004	7
Jul 8, 2020	New	$8,845,690	$4,500,006	11
Jun 19, 2019	New	$7,500,006	$5,000,004	2
Jun 19, 2019	New	$135,000	$0	5
Jun 19, 2019	New	$10,849,987	$0	5

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

AI3 Bio, Inc.

Biotechnology

Offering target: Indefinite

Filed Nov 4, 2026